Erlotinib hydrochloride, Polymorph B specifically vs. Erlotinib hydrochloride (as claimed in IN196774, Polymorphs A+B): IDENTICAL_STRUCTURE under Section 3(d)

Structures (including any salt form) are identical at the SMILES level. If these are being presented in the patent as distinct, the difference is almost certainly a POLYMORPH, PARTICLE SIZE, or other solid-state/crystal-form difference -- this cannot be determined from structure alone (no XRPD/DSC/crystal data available here). Section 3(d)'s 'polymorphs'/'particle size' categories presumptively apply; flag for manual crystallographic review. Real case: F. Hoffmann-La Roche Ltd v. Cipla Ltd, Delhi HC Division Bench, RFA(OS) 92/2012 & 103/2012, 2015 -- the separate Polymorph-B-specific application was rejected 2008-12 on Section 3(d) grounds after Cipla's opposition.